

Title: Drug Treatment & Migraines

Reference Number: RDF1007

Date of Response: 22/11/2022

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

1. *How many patients have been treated with the following drugs in the past 4 months?*

Answer: Please see table below:

Drug	Patients treated (Eastern & Northern Services)
<i>Erenumab (Aimovig) - any disease</i>	6
<i>Fremanezumab (Ajovy) - any disease</i>	91
<i>Galcanezumab (Emgality) - any disease</i>	11
<i>Botulinum Toxin (i.e., Botox, Dysport, Xeomin) - migraine ONLY</i>	76

2. *How many patients have you treated in the last 4 months for chronic migraine (15+ headache days per month) and episodic migraine (4-15 headache days per month) with the following drugs:*

Answer: In accordance with the Data Protection Act 2018 we are unable to provide figures where the number of patients/staff is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

In these cases ≤ 5 is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.

Please see table below;

Treatment	Patients treated (Eastern & Northern Services)
<i>Chronic migraine (15+ headache days / month)</i>	110
<i>Episodic migraine (4-15 headache days / month)</i>	≤ 5